poisar

Stocks · News reference

Callan JMB Announces Partnership with Rapid Dose Therapeutics for QuickStrip™ Manufacturing

Callan JMB Inc. has entered into an agreement to install a production line for Rapid Dose Therapeutics' QuickStrip™ oral thin-film technology, projecting $15 million in revenue over the first 18 months.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CJMB
Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Callan JMB Announces Arrival of Rapid Dose Therapeutics’ QuickStrip™, Resulting in $15 Million in Projected Revenue Over the Next 18 months

    Callan JMB has received a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics for installation at its Texas facility. The company projects $15 million in revenue over the next 18 months from this new pharmaceutical manufacturing platform, advancing its strategy to expand domestic pharmaceutical manufacturing and healthcare logistics capabilities.

    CJMB